Literature DB >> 27107411

Human papillomavirus infection on initiating synchronous esophageal neoplasia in patients with head and neck cancer.

Wen-Lun Wang1, Yu-Chi Wang2, Chi-Yang Chang1, Jo-Lin Lo3, Yao-Hung Kuo4, Tzer-Zen Hwang5, Chih-Chun Wang5, Lein-Ray Mo1, Jaw-Town Lin1,6,7, Ching-Tai Lee1.   

Abstract

OBJECTIVES/HYPOTHESIS: Human papillomavirus (HPV) is a risk factor for head and neck squamous cell carcinoma (HNSCC) as well as esophageal squamous cell carcinoma (ESCC). We aimed to investigate whether HPV infection underlies the field cancerization phenomenon over upper aerodigestive tract to develop synchronous multiple cancers. STUDY
DESIGN: A case control study.
METHODS: The presence and subtype of HPV-DNA sequence in cancers were examined by polymerase chain reaction and sequencing in a prospective cohort with 100 HNSCCs, 50 of which had synchronous ESCCs. The clinicopathologic characteristics were further analyzed according to the presence of HPV.
RESULTS: Twelve patients were HPV-positive, of which 11 were positive for HPV-16. The prevalence of HPV infection were not different between the synchronous and HNSCC alone groups (P = 0.357). Testing for HPV in paired HNSCC and ESCC tissues from the same patient revealed that none were concomitantly HPV-positive. Multivariate logistic regression showed drinking alcohol (odds ratio [OR], 18.75; P = 0.030), alcohol flushing (OR, 2.53; P = 0.041), and body mass index (OR, 0.77; P = 0.001) but not HPV infection were independent risk factors for synchronous phenotype. The patients with synchronous ESCCs had significantly poorer survival than those with HNSCC alone (5-year overall survival: 30% vs. 70%; log-rank P < 0.001). However, patients with HPV-positive HNSCC tend to have favorable outcome than those with HPV-negative HNSCC.
CONCLUSIONS: HPV infection plays little role in field cancerization phenomenon to initiate synchronous SCC. The synchronous HNSCC and ESCC from the same patients had no clonal relationship. Routine endoscopic examination of the esophagus should be recommended for patients with risk factors identified. LEVELS OF EVIDENCE: NA. Laryngoscope, 126:1097-1102, 2016.
© 2015 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Human papillomavirus; esophageal cancer; field cancerization; head and neck cancer; synchronous cancer

Mesh:

Substances:

Year:  2015        PMID: 27107411     DOI: 10.1002/lary.25728

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  5 in total

1.  Treatment outcomes for one-stage concurrent surgical resection and reconstruction of synchronous esophageal and head and neck squamous cell carcinoma.

Authors:  Yu-Hsuan Lin; Chun-Yen Ou; Wei-Ting Lee; Yao -Chou Lee; Tzu -Yen Chang; Yi-Ting Yen
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-07-22       Impact factor: 2.503

Review 2.  Inducible Nitric Oxide Synthase in the Carcinogenesis of Gastrointestinal Cancers.

Authors:  Graciele Almeida de Oliveira; Robert Y S Cheng; Lisa A Ridnour; Debashree Basudhar; Veena Somasundaram; Daniel W McVicar; Hugo Pequeno Monteiro; David A Wink
Journal:  Antioxid Redox Signal       Date:  2016-10-31       Impact factor: 8.401

3.  Chemoradiotherapy for Synchronous Multiple Primary Cancers with Esophageal Squamous Cell Carcinoma: a Case-control Study.

Authors:  Qi-Wen Li; Yu-Jia Zhu; Wen-Wen Zhang; Han Yang; Yao Liang; Yong-Hong Hu; Bo Qiu; Meng-Zhong Liu; Hui Liu
Journal:  J Cancer       Date:  2017-02-11       Impact factor: 4.207

4.  Altered metabolic connectivity between the amygdala and default mode network is related to pain perception in patients with cancer.

Authors:  Wen-Ying Lin; Jen-Chuen Hsieh; Ching-Chu Lu; Yumie Ono
Journal:  Sci Rep       Date:  2022-08-18       Impact factor: 4.996

Review 5.  Current Updates on Cancer-Causing Types of Human Papillomaviruses (HPVs) in East, Southeast, and South Asia.

Authors:  Chichao Xia; Sile Li; Teng Long; Zigui Chen; Paul K S Chan; Siaw Shi Boon
Journal:  Cancers (Basel)       Date:  2021-05-30       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.